Evan M. Bloch, et al., published “Comparing the Epidemiology and Health Burden of Lyme Disease and Babesiosis Hospitalizations in the United States” in the November 2022 issue of Open Forum Infectious Diseases which provides the results of a study that examined a nationally representative sample of patient hospitalizations.
Lyme disease is a bacterial disease which in the US is caused by the bacteria Borrelia burgdorferi or newly discovered Borrelia mayonii. The bacteria can attack all of the systems in the body and produce many different Lyme disease symptoms, which is why it has often been called the great imitator. Women with Lyme disease who are pregnant or are thinking of becoming pregnant need to receive appropriate care from a knowledgeable Lyme disease doctor. Information on Lyme and pregnancy can be found in this section. Guidelines which help doctors with Lyme treatment have been developed and some can be found here, as well as various photos and videos pertaining to Lyme disease bacteria.
ContagionLive published the article “Lyme Disease Vaccine Shows Antibodies 6 Months after Completion” by Senior Editor, John Parkinson, on December 1, 2022. The article provides details of the most recent investigational outcomes for Pfizer and Valneva’s Lyme disease vaccine candidate, VLA15.
Arick P.Sabin, et al., published “Clinical evaluation of a Borrelia modified two-tiered testing (MTTT) shows increased early sensitivity for Borrelia burgdorferi but not other endemic Borrelia species in a high incidence region for Lyme disease in Wisconsin” in Diagnostic Microbiology and Infectious Disease on November 9, 2022,* (version of record). Recently, a modified two-tiered testing algorithm (MTTT; ZEUS Scientific) for Borrelia burgdorferi was cleared by the FDA. This led the researchers to assess the algorithm to verify Lyme disease as well as evaluate the results in comparison to those acquired using standard two-tiered testing (STTT).
Tarsus Pharmaceuticals Announces Initiation of Phase 2a Trial of Lyme Disease Prevention Therapeutic
As reported on WDRB.com on November 9, 2022, from Tarsus Pharmaceuticals, Inc, (GLOBAl NEWSWIRE), Tarsus “is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1b clinical trial.”
Anne Spichler-Moffarah, et al., published, “Cardiac Complications of Human Babesiosis” in Clinical Infectious Diseases on August 19, 2022. The article explains that many babesiosis patients have mild to moderate expressions […]
An article in Martha Vineyard Times announced that phase 3 trials for the Valneva-Pfizer Lyme disease vaccine candidate, VLA15, will take place on the Vineyard. This trial phase will investigate the extent to which the vaccine provides protection.
Valneva and Pfizer have announced that the two companies have entered into an Equity Subscription Agreement and have updated their Collaboration and License Agreement terms for the Lyme disease vaccine candidate, VLA15. As previously announced, Pfizer plans to begin Phase 3 studies of VLA15 in Q3 2022.